A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

FOLFOXIRI plus bevacizumab is considered a standard initial therapy for metastatic colorectal cancer (mCRC). However, few prospective trials have evaluated triplet therapy plus bevacizumab in patients with RAS mutant mCRC. Patients with an age of 20 to 75 years, and unresectable, measurable tumors h...

Descripción completa

Detalles Bibliográficos
Autores principales: Satake, Hironaga, Sunakawa, Yu, Miyamoto, Yuji, Nakamura, Masato, Nakayama, Hiroshi, Shiozawa, Manabu, Makiyama, Akitaka, Kobayashi, Kazuma, Kubota, Yutaro, Mori, Misuzu, Kotaka, Masahito, Takagane, Akinori, Gotoh, Masahiro, Takeuchi, Masahiro, Fujii, Masashi, Ichikawa, Wararu, Sekikawa, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922357/
https://www.ncbi.nlm.nih.gov/pubmed/29721163
http://dx.doi.org/10.18632/oncotarget.24702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922357/
https://www.ncbi.nlm.nih.gov/pubmed/29721163
http://dx.doi.org/10.18632/oncotarget.24702

Ejemplares similares